10x Genomics Q4 2024 Earnings Conference Call Highlights
Company Participants:
Cassie Corneau – Senior Director, IR and Strategic Finance
Serge Saxonov – CEO and Co-Founder
Adam Taich – CFO
During the 10x Genomics Q4 2024 Earnings Conference Call held on February 12, 2025, the company’s executives provided key insights into their financial performance and strategic direction. Cassie Corneau, the Senior Director of Investor Relations and Strategic Finance, highlighted the company’s revenue growth and market expansion efforts. Serge Saxonov, the CEO and Co-Founder, discussed the company’s latest innovations in genomics technology, while Adam Taich, the CFO, presented the financial results for the quarter.
Conference Call Participants:
Dan Brennan – TD Cowen
Patrick Donnelly – Citi
Dan Arias – Stifel
Puneet Souda – Leerink Partners
Doug Schenkel – Wolfe Research
Tycho Peterson – Jefferies
Tejas Savant – Morgan Stanley
Dan Leonard – UBS
Subbu Nambi – Guggenheim Securities
Kyle Mikson – Canaccord Genuity
Luke Sergott – Barclays
Matt Larew – William Blair
Matt Sykes – Goldman Sachs
Michael Ryskin – Bank of America
The conference call was also attended by several analysts and investors who posed insightful questions about 10x Genomics’ future prospects and competitive landscape. Analysts from TD Cowen, Citi, Stifel, and other leading firms actively participated in the Q&A session, seeking clarity on the company’s growth strategies and market positioning.
Conclusion:
Overall, the 10x Genomics Q4 2024 Earnings Conference Call provided a comprehensive overview of the company’s performance and outlook. With a strong leadership team driving innovation and a robust financial foundation, 10x Genomics is well-positioned for sustained growth in the biotechnology sector.
How this will affect me:
As a potential investor, the insights shared during the 10x Genomics Q4 2024 Earnings Conference Call can help me make informed decisions about my investment portfolio. Understanding the company’s financial health and strategic direction can guide my investment choices in the biotechnology industry.
How this will affect the world:
10x Genomics’ continued innovation in genomics technology has the potential to revolutionize healthcare and biotechnology research on a global scale. By pushing the boundaries of scientific discovery, the company’s advancements could lead to breakthroughs in disease treatment, personalized medicine, and environmental sustainability.
